logo

Regional Content Customized for the United Kingdom (UK)

This section contains resources customized for the UK healthcare professional.

Stage II Melanoma Treatment Videos

In this video series, Professor James Larkin, Consultant Medical Oncologist, The Royal Marsden Hospital, discusses stage II melanoma. The videos address whether to treat, the risks versus benefits of treatment and the differences between the stages IIA, B and C. The content is customised to the UK. This content was recorded in March 2024.

What is stage II melanoma?

Is stage II melanoma at high risk for coming back?

How is stage IIA melanoma treated?

How is stage IIB and C melanoma treated?

How do you weigh the benefits and risks of treatment vs no treatment?

What are the side effects of treatment?

New videos from the experts!

Sequencing of Therapies in Stage IV Melanoma

In this video series, Professor James Larkin, Consultant Medical Oncologist, The Royal Marsden Hospital, discusses sequencing strategies for Stage IV melanoma. The videos address strategies for neoadjuvant and adjuvant therapy, first-line and subsequent lines of therapy, single-agent and combination immunotherapy, BRAF-targeted therapy, the management of brain metastases, clinical trials, and management of refractory disease. The videos were recorded on August 9, 2023.


When should neoadjuvant or adjuvant therapy be considered in stage IV disease?


Which immunotherapy should be used for front-line BRAF wild-type patients?


Which combination should be used after progression post PD-1 therapy?


What is the role for BRAF-targeted therapy?


How should strategies be personalised for management of brain metastases?


Strategies for refractory disease?


When should a clinical trial be considered?

New! Stage IV Decision-Support Tool

Welcome to this guide, Stage IV Melanoma Treatment Options: Making the Decision That’s Right for You. You can use this guide to discuss therapeutic options for managing Stage IV melanoma with your patients.

The document addresses

  • Stage IV melanoma clinical picture, biomarkers and pathology, and disease and patient factors involved in decision making
  • Efficacy, safety, administration, and family-planning aspects of targeted therapies, immune checkpoint inhibitors, and other therapies used for stage IV melanoma
  • Management of brain metastases, including radiation therapy
  • Clinical trials, including an overview of emerging therapies being studied
  • Survivorship and advanced care planning
  • Diagnosis (including biopsy techniques) as well as an overview of imaging
  • Practical patient resources

Developed in collaboration with Melanoma UK.

Click Here to Download

New videos from oncology experts!

Immunotherapy Combination Therapy: Current and Emerging Approaches

In this video series, Professor James Larkin, Consultant Medical Oncologist, The Royal Marsden Hospital, discusses current and emerging perspectives on the use of combination immunotherapy in oncology. These videos, developed for the UK audience, discuss the rationale for combination therapy, the data supporting the combination approaches, patient selection for combination immunotherapy versus other options, managing the more complex side effects associated with this approach, as well as new strategies of combined immunotherapy. We hope that this content will be useful for you to select and manage the best immunotherapy regimens for your cancer patients.


Rationale for Combined Immunotherapy


What are the data to support the use of combination immunotherapy?


Patient Selection for Combination Immunotherapy


Managing the Complex Adverse Effect Profile of Combination Immunotherapy


Emerging Strategies for Combination Immunotherapy

COVID-19 Vaccine Recommendations for IO Patients

In the following videos, Emmanouil Nikolousis, FRCP, FRCPath, PhD, MBA, Consultant Haematologist at University Hospitals Birmingham, discusses the use of COVID-19 vaccines in patients with cancer, particularly in those receiving immune checkpoint inhibitors (ICIs). The content is customised to the UK region. This content was recorded on  July 7, 2021 and reflects the status of vaccine approvals as of that date. For an updated list of the currently available vaccines approved in the UK, please click here: https://covid19.trackvaccines.org/country/united-kingdom-of-great-britain-and-northern-ireland/


Review of available COVID-19 vaccines


Timing of receipt of vaccines (in general and with haematopoietic cell transplantation and CAR T-cell therapies)


COVID-19 vaccines and ICIs (sequencing, monitoring, and side effects)


Addressing frequently asked questions and myths about COVID-19 vaccines


What to watch for in the future—new COVID-19 vaccine options, impact of variants, and the need for boosters

Stage III Decision-Support Materials

Updated Stage III Decision Support Tool

The Decision-Support Tool has been updated with information you need to know about outcomes for Stage III melanoma, long-term data for adjuvant therapies, and additional resources, including content specific for caregivers.

Developed in collaboration with the Melanoma UK.

Click Here to Download

New Stage III Companion Piece

Want to learn how to use the Stage III Decision-Support Tool? Peruse frequently asked questions about Stage III melanoma and learn how to use the support tool to guide your decision making.

Developed in collaboration with the Melanoma UK.

Click Here to Download

Care Step Pathways

This section provides stand-alone Care Step Pathways (CSPs) that have been customized for the UK audience. We wish to thank Emmanouil Nikolousis, FRCP, FRCPath, PhD, MBA, Consultant Haematologist at University Hospitals Birmingham, for thoughtful review of these materials.

List of CSPs

For Immunotherapy (Checkpoint Inhibitors):
Ipilimumab
Nivolumab
Pembrolizumab
Nivolumab/Ipilimumab

For Intralesional Therapy:
Talimogene laherparepvec; T-VEC

Patient Resources

Action Plans

This section contains the customizable action plans for patients with different tumor types that have been customized for the UK audience. We wish to thank Kris Griffin, patient advocate, for his helpful review of these materials.

Talimogene laherparepvec; T-VEC

Pembrolizumab

Nivolumab

Nivolumab/Ipilimumab

Ipilimumab

Copyright ©2022- - AIM with Immunotherapy. All rights reserved.